Biologic and Targeted Synthetic DMARDs may Improve Work Productivity in Psoriatic Arthritis: Study
Psoriatic arthritis (PsA) not only affects joint health but also significantly impacts work productivity and leisure activities. Previous studies have highlighted the substantial burden of PsA on patients' ability to work and engage in daily activities. PsA is associated with reduced health-related quality of life and various comorbidities, leading to impaired social participation and functional limitations.
A recent study has found that targeted DMARD therapy improves the quality and ability to work regularly in PsA patients. This study was published in the journal Arthritis Research Therapy by Gossec L and colleagues.
A systematic literature review and meta-analysis were conducted to evaluate the impact of b/tsDMARD treatment on work productivity in PsA patients. Studies published between January 2010 and October 2021 were included, focusing on outcomes related to absenteeism, presenteeism, and activity impairment using the Work Productivity and Activity Impairment Questionnaire (WPAI).
The key findings were:
Twelve studies, comprising 10 randomized controlled trials and 2 observational studies, were analyzed.
Among employed PsA patients (n = 3741), baseline scores indicated significant impairment in work productivity and activity participation.
After 24 weeks of b/tsDMARD treatment, substantial improvements were observed across all WPAI domains, with absolute mean improvements of 2.4 percentage points for absenteeism, 17.8% for presenteeism, 17.6% for total work productivity impairment, and 19.3% for activity impairment.
These findings corresponded to a 41% relative improvement in total work productivity.
The study underscores the significant impact of PsA on work productivity and highlights the effectiveness of b/tsDMARDs in mitigating these effects. Despite limitations, including the exclusive use of WPAI and variations in cost estimation methods, the results provide valuable insights into the economic benefits of b/tsDMARD treatment in PsA.
Measurement of work impact is essential for assessing the economic burden and value of therapies in PsA. The study demonstrates meaningful improvements in work productivity following 24 weeks of b/tsDMARD treatment, emphasizing the importance of early and effective management strategies for PsA patients to enhance their overall well-being and economic outcomes.
Reference:
Gossec L, Humphries B, Rutherford M, Taieb V, Willems D, Tillett W. Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis. Arthritis Res Ther. 2024;26(1):50. Published 2024 Feb 15. doi:10.1186/s13075-024-03282-0
